ALX Oncology's (ALXO) Overweight Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of ALX Oncology (NASDAQ:ALXO - Free Report) in a research note published on Friday, Benzinga reports.

ALXO has been the topic of a number of other research reports. HC Wainwright reiterated a buy rating and issued a $20.00 target price on shares of ALX Oncology in a research report on Wednesday. Stifel Nicolaus reiterated a hold rating and issued a $14.00 target price (up previously from $10.00) on shares of ALX Oncology in a research report on Friday, March 8th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of Moderate Buy and an average target price of $18.83.

ALX Oncology Price Performance

Shares of NASDAQ ALXO traded down $0.35 during mid-day trading on Friday, reaching $13.03. 359,332 shares of the company were exchanged, compared to its average volume of 394,765. ALX Oncology has a 52 week low of $3.94 and a 52 week high of $17.42. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $653.45 million, a PE ratio of -3.58 and a beta of 1.58. The company's 50 day moving average price is $13.61 and its 200 day moving average price is $11.57.

ALX Oncology (NASDAQ:ALXO - Get Free Report) last posted its quarterly earnings data on Thursday, March 7th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.84) by ($0.09). Sell-side analysts forecast that ALX Oncology will post -3.33 earnings per share for the current fiscal year.

Insider Buying and Selling at ALX Oncology

In other ALX Oncology news, insider Jaume Pons sold 20,000 shares of the business's stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $11.15, for a total value of $223,000.00. Following the transaction, the insider now owns 628,359 shares in the company, valued at $7,006,202.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, insider Jaume Pons sold 20,000 shares of the business's stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $11.15, for a total transaction of $223,000.00. Following the transaction, the insider now owns 628,359 shares in the company, valued at $7,006,202.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Jason Lettmann purchased 4,400 shares of ALX Oncology stock in a transaction that occurred on Thursday, March 14th. The shares were bought at an average price of $11.31 per share, for a total transaction of $49,764.00. Following the transaction, the chief executive officer now directly owns 171,620 shares of the company's stock, valued at $1,941,022.20. The disclosure for this purchase can be found here. Corporate insiders own 50.30% of the company's stock.

Hedge Funds Weigh In On ALX Oncology

Several hedge funds and other institutional investors have recently modified their holdings of ALXO. Swiss National Bank boosted its stake in ALX Oncology by 8.5% during the first quarter. Swiss National Bank now owns 19,200 shares of the company's stock worth $324,000 after acquiring an additional 1,500 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in ALX Oncology by 21.6% during the first quarter. JPMorgan Chase & Co. now owns 19,237 shares of the company's stock worth $326,000 after acquiring an additional 3,417 shares in the last quarter. MetLife Investment Management LLC boosted its stake in ALX Oncology by 58.5% during the first quarter. MetLife Investment Management LLC now owns 10,745 shares of the company's stock worth $182,000 after acquiring an additional 3,965 shares in the last quarter. BlackRock Inc. boosted its stake in ALX Oncology by 1.1% during the first quarter. BlackRock Inc. now owns 1,355,478 shares of the company's stock worth $22,907,000 after acquiring an additional 14,907 shares in the last quarter. Finally, Federated Hermes Inc. bought a new stake in ALX Oncology during the first quarter worth about $914,000. Hedge funds and other institutional investors own 97.97% of the company's stock.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.